Lip filler at 18 in Florida: adult consent is not the same as the FDA-labeled age
Florida generally recognizes legal adulthood at 18, while FDA-approved dermal-filler uses have product-specific age boundaries. An adult's ability to consent does not make an under-22 lip-filler use FDA approved or determine whether a clinician should offer it.
In Florida, turning 18 generally establishes adult legal capacity, but it does not make every cosmetic treatment FDA approved for that age. FDA describes approved dermal-filler uses in adults 22 or older, and the exact product’s labeling controls the age and anatomical indication. For an adult aged 18–21, consent, off-label status, and a clinician’s decision to offer lip filler are separate questions.123
Two age thresholds answer different questions
Florida Statutes section 743.07 generally removes the disability of nonage at 18 for rights, privileges, and obligations, subject to its provisions. That is a legal-capacity rule. It does not rewrite a medical product’s studied population or approved indication.1
FDA’s filler information addresses the products and uses the agency has reviewed. For example, the Restylane Kysse approval record specifies lip augmentation and correction of upper perioral rhytids in patients over 21.3 A clinic saying “we accept adults” has not yet answered whether the proposed use matches that label.
This guide concerns adults 18–21. It is not a complete consent guide for minors, emancipation, guardianship, or other special circumstances.
Put the exact product beside the proposed use
Ask the clinician to name the filler and show the applicable labeling. A general statement that a brand is FDA approved does not identify which formulation, treatment area, age group, or use is approved.
| Question | Record that answers it |
|---|---|
| Am I being treated as an adult for consent? | Applicable Florida law and the individual's circumstances |
| Is this product FDA approved? | Exact product's FDA record |
| Does this age and lip use match the indication? | Current product labeling |
| Will this clinician offer the procedure? | Individual assessment, professional judgment, and practice policy |
None of the four rows can substitute for another. A practice may decline an elective procedure even when a person can legally consent. Equally, a clinic’s willingness to provide it does not establish that the use is FDA approved for the patient’s age.
Ask for an explicit off-label explanation
Off-label use means a product is used outside its approved labeling; it is not a new approval granted by the treating practice. Federal law preserves a practitioner’s authority to administer a legally marketed device within a legitimate practitioner-patient relationship, while retaining specified federal restrictions and limits on promotion.4 That provision does not settle Florida scope of practice or establish that a particular under-22 use is suitable.
For an under-22 lip-filler consultation, ask: “Which part of the proposed use is outside the label, what evidence informs your recommendation for someone my age, and what alternatives are you discussing?” The answer should not rely solely on how common the procedure seems online.
Off-label status should not be presented as automatic proof of illegality or automatic proof of suitability. Treomark cannot determine an individual’s eligibility from age alone. The useful outcome is an understandable explanation of the evidence boundary and the clinician’s reasoning.
A signature does not resolve the age-and-evidence question
A consent form may include a general acknowledgment of off-label use. Ask whether the conversation identifies the exact issue rather than hiding it in a broad paragraph covering many unrelated procedures.
The Florida informed-consent guide addresses the broader discussion of the procedure, alternatives, and substantial risks. Here, the additional task is to make the age boundary visible in that discussion. Keep the product name and written plan with the consent record.
If someone else pays, ask the practice to clarify communication and privacy arrangements. Payment, the patient’s decision, and permission to share health information should not be assumed to be the same authorization.
Assess the offer without a deadline attached
An appointment tied to a birthday, trip, or promotion can make the decision feel urgent. Ask whether the consultation can be completed without committing to injection that day and what happens to a deposit if the clinician does not recommend proceeding.
Discuss the appearance change in concrete terms rather than requesting a copied photograph. Ask what the clinician considers realistic, what would cause them to decline treatment, and how follow-up would work. These questions are useful whether the eventual decision is to proceed, wait, or choose no procedure.
FDA describes serious filler risks, including unintended injection into blood vessels.2 The assessment and emergency arrangements therefore matter alongside the age discussion; being an adult does not remove those risks.
What a complete answer sounds like
Before paying for treatment, the record should identify the exact filler, intended lip use, age-related labeling, any off-label element, alternatives, and the clinician responsible for follow-up.
The decisive distinction is simple: “I can consent as an adult” and “this product is approved for this use at my age” are different statements. A good consultation explains both without treating either as the entire decision.
Sources
- Florida Senate. Florida Statutes section 743.07: Rights, privileges, and obligations of persons 18 years of age or older. General adult legal capacity at 18, subject to the statute's exceptions; not product approval or an exhaustive rule for minors. Accessed .
- U.S. Food and Drug Administration. Dermal fillers (soft tissue fillers). FDA describes approved filler uses in adults 22 or older and product-specific indications and risks. Accessed .
- U.S. Food and Drug Administration. Restylane Kysse premarket approval supplement P140029/S021. Concrete lip-augmentation approval in patients over 21; an example, not an endorsement or a rule for every product. Accessed .
- U.S. Government Publishing Office. 21 U.S.C. section 396: Practice of medicine. Federal device practice-of-medicine provision and its limits; not a Florida scope determination or approval of a specific off-label use. Accessed .